Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

Gilead Sciences will present new research at the 2025 European Association for the Study of the Liver (EASL) Congress, highlighting advancements in treating liver diseases. Key data include findings on Livdelzi (seladelpar) for primary biliary cholangitis (PBC), showing effectiveness in reducing pruritus and improving biochemical response across various patient groups. Additional presentations will feature results from studies on bulevirtide for hepatitis delta virus (HDV), including long-term virologic response after treatment cessation, and a novel hepatitis B virus (HBV) therapeutic vaccine showing early promise toward functional cure goals. Real-world data on hepatitis C virus (HCV) treatments will also be presented, supporting the global applicability of treatment guidelines. Gilead remains committed to addressing unmet needs in liver disease through scientific innovation and partnerships.